Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

VACCINE AGAINST DEMENTIA

A research team, led by scientists at the Institute for Molecular Medicine and University of California at Irvine, has reported success with a vaccine against Alzheimer’s dementia tested in mice.
The vaccine spurs the body to create antibodies that remove, and then prevent, the agglomeration of amyloid and tau proteins in the brain. These two proteins are thought to cause the symptoms of Alzheimer’s disease by flummoxing communication among brain cells.
In mice genetically engineered to be susceptible to Alzheimer’s, the vaccine, dubbed Advax, prevented the proteins’ build-up when mice were injected before symptoms appeared. Advax also cleared the proteins in mice already showing symptoms.
Other attempts at vaccines have targeted either amyloid or tau proteins. Evidence hints that the proteins work together to cause dementia. Advax combines ingredients that target both.
Human trials are being planned.
TRENDPOST: Other trials have shown success in reversing Alzheimer’s both by injection and by lifestyle management. With the addition of a vaccine and similar treatments, Alzheimer’s will be a preventable, and curable, illness by 2035.
 

Comments are closed.